Implanet begins to convince in the United States

0
6


Innovative Gironde society in the world of health, with the development of a new generation of vertebral implants, its Jazz units, and knee prostheses, Implanet, which is facing serious financial turbulence, seems to have the means to straighten the bar. At the end of the first half of 2019 the company headed by Ludovic Lastennet, headquartered in Martillac, also based in Boston (United States), achieved a turnover of € 3.8 million, up + 5% compared to the same period in 2018. An evolution that is mainly driven by the increase in sales of Jazz devices, which, at € 2.3 million at June 30, show an increase of 8% over one year.

Knee prostheses remained stable at € 1.4m between the first half of 2018 and 2019. However, the follow-up of sales trends between the first and second quarters of 2019 deepened the outlook. The sharp rise in activity on technologies for the treatment of spinal pathologies is not found on those of the knee, which confirms the quarterly trend. While Jazz recorded a 9.1% increase in sales between the two quarters (from 1140 K € to 1244 K €), knee prostheses were down 17.9% over the same period (817 K € to 670 K €). The turnover trend is just positive between the first two quarters of 2019, at + 0.5%. As a result, sales rose from € 1.904k in the first quarter to € 1.915k in the second.

300 convertible bonds at 10,000 euros each

"The positive trend of the first quarter was confirmed with an increase of 8% this quarter.The focus of our teams on the strategic priorities of commercial development associated with a prudent financial management of our operations is beginning to bear fruit. The Kico Knee and SeaSpine partnerships are encouraging, as well as the first surgeries performed with Jazz Cap in the United States and Europe "commented Ludovic Lastennet.

The evolution of the business is all the more promising for Implanet as its market was mainly driven by sales in the United States, at + 11%, at € 1.2 million. Another positive sign: the leap made on the European market (excluding France) to +52%, starting from very low it is true since this very strong increase results in 370,000 euros in sales. In contrast, the market posted a significant decline during the same period, to -7%, "due to a delay on some surgeries in the month of July" observes the management.

The good results recorded in the United States seem to show that the signing of the partnership agreement, announced last February 21, between Implanet and the American company SeaSpine, responsible for marketing the spinal implants Jazz in the United States, begins to wear its fruits.

An international medical technology company, SeaSpine specializes in surgical solutions for the treatment of spinal pathologies. Furthermore, the Implanet group recalls that, since April 2019, it has benefited from a bond credit facility opened by Nice & Green for a period of one year, in the form of 300 convertible bonds with a par value of 10,000 euros. Financing line that will secure the treasury of the company Gironde. Implanet then relies on its partnerships signed with SeaSpine, for Jazz Cap devices (equipped with screws compatible with SeaSpine formats) and Kico Knee to ensure its take-off.



Source link
https://objectifaquitaine.latribune.fr/innovation/2019-08-30/implanet-commence-a-convaincre-aux-etats-unis-826731.html

LEAVE A REPLY

Please enter your comment!
Please enter your name here

4 × two =